Base de dados : MEDLINE
Pesquisa : D08.622.432 [Categoria DeCS]
Referências encontradas : 3967 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 397 ir para página                         

  1 / 3967 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29235093
[Au] Autor:Di Minno MND; Napolitano M; Dolce A; Mariani G; STER Study Group
[Ad] Endereço:Department of Advanced Biomedical Sciences, Federico II University, Naples, Italy.
[Ti] Título:Role of clinical and laboratory parameters for treatment choice in patients with inherited FVII deficiency undergoing surgical procedures: evidence from the STER registry.
[So] Source:Br J Haematol;180(4):563-570, 2018 02.
[Is] ISSN:1365-2141
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Perioperative bleeding is a major concern in patients with factor VII (FVII) deficiency. Evaluating data of 95 FVII-deficient patients undergoing 110 surgical procedures (61 major, 49 minor), we assessed the impact of type of surgery, bleeding phenotype and FVII coagulant activity (FVII:C) levels on perioperative replacement therapy (RT). Compared to those with higher FVII:C levels, patients with <3% FVII:C received a higher number of RT doses (8 vs. 2, P = 0·003) for a longer RT duration (3 days vs. 1 day, P = 0·001), with no difference in RT dose. Similarly, patients with a history of major bleeds received a higher number of RT doses (8·5 vs. 2-3, P = 0·013) for a longer RT duration (2 days vs. 1 day, P = 0·005) as compared to those with a history of minor bleeds or to asymptomatic patients. No difference in RT was found among major and minor surgical procedures. Overall, multivariate analysis showed that history of major bleeding was the only independent predictor of number of RT doses (ß = 0·352, P = 0·001) and RT duration (ß = 0·405, P = 0·018). Overall, a ≈20 µg/kg perioperative RT was efficacious in 95·5% of cases. The infusion should be repeated ≈8 times in high-risk subsets (i.e. patients with a history of major bleeding).
[Mh] Termos MeSH primário: Deficiência do Fator VII/diagnóstico
Deficiência do Fator VII/cirurgia
[Mh] Termos MeSH secundário: Adolescente
Adulto
Tomada de Decisão Clínica
Terapia Combinada
Gerenciamento Clínico
Fator VII/administração & dosagem
Deficiência do Fator VII/epidemiologia
Feminino
Hemorragia/etiologia
Hemorragia/cirurgia
Seres Humanos
Masculino
Meia-Idade
Sistema de Registros
Procedimentos Cirúrgicos Operatórios/métodos
Avaliação de Sintomas
Resultado do Tratamento
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
9001-25-6 (Factor VII)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180221
[Lr] Data última revisão:
180221
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171214
[St] Status:MEDLINE
[do] DOI:10.1111/bjh.15055


  2 / 3967 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28843429
[Au] Autor:Grille Coronel L; Acierno JP; Ermácora MR
[Ad] Endereço:Departamento de Ciencia y Tecnología, Universidad Nacional de Quilmes, Roque Saenz Pena 352, B1876BXD Bernal, Pcia. de Buenos Aires, Argentina.
[Ti] Título:Ultracompact states of native proteins.
[So] Source:Biophys Chem;230:36-44, 2017 Nov.
[Is] ISSN:1873-4200
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:A statistical analysis of circa 20,000 X-ray structures evidenced the effects of temperature of data collection on protein intramolecular distances and degree of compaction. Identical chains with data collected at cryogenic ultralow temperatures (≤160K) showed a radius of gyration (R ) significantly smaller than at moderate temperatures (≥240K). Furthermore, the analysis revealed the existence of structures with a R significantly smaller than expected for cryogenic temperatures. In these ultracompact cases, the unusually small R could not be specifically attributed to any experimental parameter or crystal features. Ultracompaction involves most atoms and results in their displacement toward the center of the molecule. Ultracompact structures on average have significantly shorter van der Waals and hydrogen bonds than expected for ultralow temperature structures. In addition, the number of van der Waals contacts was larger in ultracompact than in ultralow temperature structures. The structure of these ultracompact states was analyzed in detail and the implication and possible causes of the phenomenon are discussed.
[Mh] Termos MeSH primário: Proteínas/química
[Mh] Termos MeSH secundário: Animais
Bovinos
Quimotripsina/química
Ciclinas/química
Bases de Dados de Proteínas
Fator VII/química
Antígenos HLA-DR/química
Seres Humanos
Ligações de Hidrogênio
Estrutura Terciária de Proteína
Eletricidade Estática
Temperatura Ambiente
Tripsina/química
Microglobulina-2 beta/química
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Cyclins); 0 (HLA-DR Antigens); 0 (Proteins); 0 (beta 2-Microglobulin); 9001-25-6 (Factor VII); EC 3.4.21.1 (Chymotrypsin); EC 3.4.21.1 (alpha-chymotrypsin); EC 3.4.21.4 (Trypsin)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171030
[Lr] Data última revisão:
171030
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170828
[St] Status:MEDLINE


  3 / 3967 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28726667
[Au] Autor:Vasylyev D; Chernobay L; Vasylieva O; Oliinyk M; Vashuk M
[Ad] Endereço:1Kharkiv Medical Academy of Postgraduate Study; 2Kharkiv National Medical University, Ukraine.
[Ti] Título:CLINICAL AND GENETIC PECULIARITIES OF VASCULAR MANIFESTATIONS OF ANTIPHOSPHOLIPID SYNDROME (CASE REPORT).
[So] Source:Georgian Med News;(267):114-119, 2017 Jun.
[Is] ISSN:1512-0112
[Cp] País de publicação:Georgia (Republic)
[La] Idioma:eng
[Ab] Resumo:Pathogenetic mechanisms of the development of antiphospholipid syndrome (APS) are considered in the article, which is the basis for the development of clinical manifestations and laboratory markers of APS. The modern literature data are analyzed, according to which the presence of antiphospholipid antibodies is a hypercoagulable background, and the formation of thrombi occurs under the influence of other allowing procoagulation factors. The classification of the main types of hereditary thrombophilia is given, which is the primary disorder, against the background of which an autoimmune thrombosis APS develops. A clinical observation of a young age patient is given, whose heterozygous carriage of mutations in the genes responsible for blood coagulation (F7, PAI-1 and ITGB3-ß-integrin), as well as homozygous carriage of a mutation in the MTRR gene associated with a violation of homocysteine methylation, APS was developed, which led to the processes of thrombosis. Timely diagnosis and individually developed pathogenetic therapy allow avoiding life-threatening complications of APS and improving the patients' quality of life. A conclusion about the need for APS and hereditary thrombophilias' examination to all patients of young age with unprovoked thrombosis of deep veins of lower extremities and PE was made.
[Mh] Termos MeSH primário: Síndrome Antifosfolipídica/genética
Fator VII/genética
Ferredoxina-NADP Redutase/genética
Integrina beta3/genética
Inibidor 1 de Ativador de Plasminogênio/genética
[Mh] Termos MeSH secundário: Adulto
Síndrome Antifosfolipídica/fisiopatologia
Heterozigoto
Homozigoto
Seres Humanos
Masculino
Mutação
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (ITGB3 protein, human); 0 (Integrin beta3); 0 (Plasminogen Activator Inhibitor 1); 0 (SERPINE1 protein, human); 9001-25-6 (Factor VII); EC 1.18.1.- (methionine synthase reductase); EC 1.18.1.2 (Ferredoxin-NADP Reductase)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170919
[Lr] Data última revisão:
170919
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170721
[St] Status:MEDLINE


  4 / 3967 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Covas, Dimas Tadeu
Texto completo
[PMID]:28651975
[Au] Autor:Corrêa de Freitas MC; Bomfim AS; Mizukami A; Picanço-Castro V; Swiech K; Covas DT
[Ad] Endereço:Center for Cell-based Therapy and Regional Blood Center of Ribeirão Preto, Laboratory of Biotechnology, University of São Paulo, Ribeirão Preto, São Paulo, Brazil; Department of Medical Clinic, Medical School of Ribeirão Preto, University of São Paulo, Ribeirão Preto, São Paulo, Brazil. Electronic a
[Ti] Título:Production of coagulation factor VII in human cell lines Sk-Hep-1 and HKB-11.
[So] Source:Protein Expr Purif;137:26-33, 2017 Sep.
[Is] ISSN:1096-0279
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Recombinant factor VII (rFVII) is the main therapeutic choice for hemophilia patients who have developed inhibitory antibodies against conventional treatments (FVIII and FIX). Because of the post-translational modifications, rFVII needs to be produced in mammalian cell lines. In this study, for the first time, we have shown efficient rFVII production in HepG2, Sk-Hep-1, and HKB-11 cell lines. Experiments in static conditions for a period of 96 h showed that HepG2-FVII produced the highest amounts of rhFVII, with an average of 1843 ng/mL. Sk-hep-1-FVII cells reached a maximum protein production of 1432 ng/mL and HKB-11-FVII cells reached 1468 ng/mL. Sk-Hep-1-rFVII and HKB-11-rFVII were selected for the first step of scale-up. Over 10 days of spinner flask culture, HKB-11 and SK-Hep-1 cells showed a cumulative production of rFVII of 152 µg and 202.6 µg in 50 mL, respectively. Thus, these human cell lines can be used for an efficient production of recombinant FVII. With more investment in basic research, human cell lines can be optimized for the commercial production of different bio therapeutic proteins.
[Mh] Termos MeSH primário: Fator VII
Expressão Gênica
[Mh] Termos MeSH secundário: Linhagem Celular
Fator VII/biossíntese
Fator VII/genética
Fator VII/isolamento & purificação
Seres Humanos
Proteínas Recombinantes/biossíntese
Proteínas Recombinantes/genética
Proteínas Recombinantes/isolamento & purificação
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Recombinant Proteins); 9001-25-6 (Factor VII)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170807
[Lr] Data última revisão:
170807
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170628
[St] Status:MEDLINE


  5 / 3967 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28338598
[Au] Autor:Christie SA; Kornblith LZ; Howard BM; Conroy AS; Kunitake RC; Nelson MF; Hendrickson CM; Calfee CS; Callcut RA; Cohen MJ
[Ad] Endereço:From the Department of Surgery (S.A.C., L.Z.K., B.M.H., A.S.C., R.C.K., M.F.N., C.M.H., C.S.C., R.A.C.), San Francisco General Hospital and the University of California, San Francisco, California; and Denver Health Medical Center and the University of Colorado (M.J.C.), Denver, Colorado.
[Ti] Título:Characterization of distinct coagulopathic phenotypes in injury: Pathway-specific drivers and implications for individualized treatment.
[So] Source:J Trauma Acute Care Surg;82(6):1055-1062, 2017 Jun.
[Is] ISSN:2163-0763
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: International normalized ratio (INR) and partial thromboplastin time (PTT) are used interchangeably to diagnose acute traumatic coagulopathy but reflect disparate activation pathways. In this study, we identified injury/patient characteristics and coagulation factors that drive contact pathway, tissue factor pathway (TF), and common pathway dysfunction by examining injured patients with discordant coagulopathies. We hypothesized that patients with INR/PTT discordance reflect differing phenotypes representing contact versus tissue factor pathway perturbations and that characterization will provide targets to guide individualized resuscitation. METHODS: Plasma samples were prospectively collected from 1,262 critically injured patients at a single Level I trauma center. Standard coagulation measures and an extensive panel of procoagulant and anticoagulant factors were assayed and analyzed with demographic and outcome data. RESULTS: Fourteen percent of patients were coagulopathic on admission. Among these, 48% had abnormal INR and PTT (BOTH), 43% had isolated prolonged PTT (PTT-CONTACT), and 9% had isolated elevated INR (INR-TF). PTT-CONTACT and BOTH had lower Glasgow Coma Scale score than INR-TF (p < 0.001). INR-TF had decreased factor VII activity compared with PTT-CONTACT, whereas PTT-CONTACT had decreased factor VIII activity compared with INR-TF. All coagulopathic patients had factor V deficits, but activity was lowest in BOTH, suggesting an additive downstream effect of disordered activation pathways. Patients with PTT-CONTACT received half as much packed red blood cell and fresh frozen plasma as did the other groups (p < 0.001). Despite resuscitation, mortality was higher for coagulopathic patients; mortality was highest in BOTH and higher in PTT-CONTACT than in INR-TF (71%, 60%, 41%; p = 0.04). CONCLUSIONS: Discordant phenotypes demonstrate differential factor deficiencies consistent with dysfunction of contact versus tissue factor pathways with additive effects from common pathway dysfunction. Recognition and treatment of pathway-specific factor deficiencies driving different coagulopathic phenotypes in injured patients may individualize resuscitation and improve outcomes. LEVEL OF EVIDENCE: Prognostic/epidemiological study, level II.
[Mh] Termos MeSH primário: Transtornos da Coagulação Sanguínea/etiologia
Ferimentos e Lesões/complicações
[Mh] Termos MeSH secundário: Adulto
Transtornos da Coagulação Sanguínea/sangue
Transtornos da Coagulação Sanguínea/diagnóstico
Transtornos da Coagulação Sanguínea/terapia
Transfusão de Sangue/estatística & dados numéricos
Fator VII/análise
Fator VIII/análise
Feminino
Escala de Coma de Glasgow
Seres Humanos
Coeficiente Internacional Normatizado
Masculino
Meia-Idade
Tempo de Tromboplastina Parcial
Ressuscitação
Centros de Traumatologia
Ferimentos e Lesões/sangue
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
9001-25-6 (Factor VII); 9001-27-8 (Factor VIII)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170801
[Lr] Data última revisão:
170801
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170325
[St] Status:MEDLINE
[do] DOI:10.1097/TA.0000000000001423


  6 / 3967 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28245651
[Au] Autor:Jo BC; Yoon HJ; Ok MR; Wu S
[Ad] Endereço:Department of Physics, Pukyong National University, Busan 608-737, South Korea.
[Ti] Título:Molecular dynamics simulation of cytotoxicity of graphene nanosheets to blood-coagulation protein.
[So] Source:Biointerphases;12(1):01A403, 2017 Feb 28.
[Is] ISSN:1559-4106
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Graphene is a nanomaterial that is widely used in electronics, biomedicine, and drug-delivery systems. Although it has many industrial applications, the cytotoxicity of graphene has not been sufficiently studied. In this study, the authors used molecular dynamics simulation to investigate how a graphene nanosheet affects a blood-coagulation protein, namely, a tissue factor/FVIIa binary complex bound to a lipid bilayer membrane, in a 4:1 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine/1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-l-serine lipid bilayer mixture. Based on the results, the authors suggest a mechanism for the cytotoxicity of graphene nanosheets to blood-coagulation protein at the molecular level.
[Mh] Termos MeSH primário: Fator VII/metabolismo
Grafite/toxicidade
Bicamadas Lipídicas/metabolismo
Nanoestruturas/toxicidade
Tromboplastina/metabolismo
[Mh] Termos MeSH secundário: Simulação de Dinâmica Molecular
Ligação Proteica
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Lipid Bilayers); 7782-42-5 (Graphite); 9001-25-6 (Factor VII); 9035-58-9 (Thromboplastin)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170913
[Lr] Data última revisão:
170913
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170302
[St] Status:MEDLINE
[do] DOI:10.1116/1.4977076


  7 / 3967 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28176610
[Au] Autor:Girolami A; Cosi E; Ferrari S; Girolami B; Lombardi AM
[Ad] Endereço:a Department of Medicine , University of Padua Medical School , Padua , Italy.
[Ti] Título:Bleeding manifestations in heterozygotes with congenital FVII deficiency: a comparison with unaffected family members during a long observation period.
[So] Source:Hematology;22(6):375-379, 2017 Jul.
[Is] ISSN:1607-8454
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:OBJECTIVES: To determine whether heterozygotes with FVII deficiency have a bleeding tendency or not. PATIENTS AND METHODS: Eighty-four patients (OK) heterozygous for FVII deficiency, at the onset of the study, were paired with unaffected family members and followed for a long period of time (mean 22.6 years) for the occurrence of bleeding. Diagnosis of heterozygosis had to be based on family studies, clotting, immunological assays and genetic analysis. RESULTS: The mean FVII activity level was 0.51 IU/dl (range 35-65) and 94 IU/dl (range 88-118) in the heterozygotes and in the normal counterparts, respectively. Documented bleeding manifestations occurred in eight heterozygotes and in seven normal subjects. Statistical analysis of the difference was not significant. Bleeding manifestations were easy bruising, bleeding after tooth extractions, menorrhagia, epistaxis with no difference among the two groups. There was no strict correlation between bleeding and FVII activity levels. CONCLUSIONS: The study indicates that heterozygotes for FVII deficiency show rare bleeding manifestations which are also present in the unaffected family members with normal FVII levels. This indicates that Factor VII activity levels played no role in the occurrence of the bleeding symptoms. Furthermore, FVII levels of around 0.40 IU/dl are capable of assuring a normal hemostasis.
[Mh] Termos MeSH primário: Deficiência do Fator VII/complicações
Deficiência do Fator VII/genética
Fator VII/genética
Hemorragia/diagnóstico
Hemorragia/etiologia
Heterozigoto
Mutação
[Mh] Termos MeSH secundário: Adolescente
Adulto
Testes de Coagulação Sanguínea
Ativação Enzimática
Deficiência do Fator VII/terapia
Família
Feminino
Seres Humanos
Masculino
Fenótipo
Valores de Referência
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
9001-25-6 (Factor VII)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170707
[Lr] Data última revisão:
170707
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170209
[St] Status:MEDLINE
[do] DOI:10.1080/10245332.2017.1286540


  8 / 3967 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27676288
[Au] Autor:Peng L; Xiong W; Cai Y; Chen Y; He Y; Yang J; Jin J; Li H
[Ad] Endereço:a The Key Laboratory of Industrial Biotechnology, Ministry of Education , School of Biotechnology, Jiangnan University , Wuxi , China.
[Ti] Título:A simple, rapid method for evaluation of transfection efficiency based on fluorescent dye.
[So] Source:Bioengineered;8(3):225-231, 2017 May 04.
[Is] ISSN:2165-5987
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Enhanced transfection efficiency of transient gene expression (TGE) and electroporation is a useful approach for improvement of recombinant therapeutic proteins in mammalian cells. A novel method is described here in which CHO cells expressing recombinant FVII (rFVII) were labeled with fluorescent dye and analyzed by confocal microscopy. Cells with or without rFVII encoding gene were detectable by flow cytometry. Thus, we were able to distinguish positive cells (with rFVII encoding gene) and quantify their percentages. We evaluated the effects of varying electroporation conditions (voltage, number of repetitions, plasmid amount, carrier DNA) in order to optimize transfection efficiency. The highest transfection efficiency achieved was ∼86%. The method described here allows rapid evaluation of transfection efficiency without co-expression of reporter genes. In combination with appropriate antibodies, the method can be extended to evaluation of transfection efficiency in cells expressing other recombinant proteins.
[Mh] Termos MeSH primário: Fator VII/genética
Fator VII/metabolismo
Proteínas de Fluorescência Verde
Microscopia de Fluorescência/métodos
Proteínas Recombinantes/genética
Proteínas Recombinantes/metabolismo
Transfecção/métodos
[Mh] Termos MeSH secundário: Animais
Células CHO
Cricetulus
Eletroporação/métodos
Corantes Fluorescentes
Imagem Molecular/métodos
Reprodutibilidade dos Testes
Sensibilidade e Especificidade
Coloração e Rotulagem/métodos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Fluorescent Dyes); 0 (Recombinant Proteins); 147336-22-9 (Green Fluorescent Proteins); 9001-25-6 (Factor VII)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171030
[Lr] Data última revisão:
171030
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160928
[St] Status:MEDLINE
[do] DOI:10.1080/21655979.2016.1222995


  9 / 3967 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26919454
[Au] Autor:Deshpande R; Ghosh K; Shetty S
[Ad] Endereço:Department of Haemostasis and Thrombosis, National Institute of Immunohaematology (ICMR), Mumbai, India.
[Ti] Título:Synergistic effect of factor VII gene polymorphisms causing mild factor VII deficiency in a case of severe factor X deficiency.
[So] Source:Blood Coagul Fibrinolysis;28(1):105-106, 2017 Jan.
[Is] ISSN:1473-5733
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Congenital combined deficiency of coagulation factors VII and X are mainly attributed to large deletions involving both the genes in chromosome 13 or occasionally due to the coincidental occurrence of independently occurring mutations. We report the molecular basis of congenital combined deficiency of factors VII and X in a 6-year-old female child. Direct DNA sequencing of both factor VII (F7) and factor X (F10) genes showed a novel homozygous missense mutation p.Cys90Tyr (c.307G>A) in exon 4 of F10. No mutations were detected in F7; however, the patient was homozygous for three polymorphic alleles known to be associated with reduced factor VII levels. The present case illustrates the synergistic effect of multiple polymorphisms resulting in phenotypic factor VII deficiency in the absence of a pathogenic mutation.
[Mh] Termos MeSH primário: Deficiência do Fator VII/genética
Fator VII/genética
Deficiência do Fator X/genética
[Mh] Termos MeSH secundário: Criança
Feminino
Seres Humanos
Mutação
Polimorfismo Genético
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
9001-25-6 (Factor VII)
[Em] Mês de entrada:1703
[Cu] Atualização por classe:170817
[Lr] Data última revisão:
170817
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160227
[St] Status:MEDLINE
[do] DOI:10.1097/MBC.0000000000000544


  10 / 3967 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26873107
[Au] Autor:Slomka A; Switonska M; Sinkiewicz W; Zekanowska E
[Ad] Endereço:1 Department of Pathophysiology, Nicolaus Copernicus University in Torun, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Bydgoszcz, Poland.
[Ti] Título:Assessing Circulating Factor VIIa-Antithrombin Complexes in Acute Ischemic Stroke: A Pilot Study.
[So] Source:Clin Appl Thromb Hemost;23(4):351-359, 2017 May.
[Is] ISSN:1938-2723
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:AIM: The goal of this study was to determine the levels of factor VII (FVII), factor VIIa-antithrombin complexes (FVIIa-AT), total tissue factor (TF), and tissue factor-bearing microparticles (MPs-TF) in patients with acute ischemic stroke. Further, we sought evidence of an association between hemostatic markers, time of blood sampling, type of treatment, and patient outcomes. METHODS: Venous blood samples were collected from 33 patients on the first day and on the seventh day after stroke diagnosis. Age-matched controls were also included (n = 20). Plasma levels of FVII, FVIIa-AT, total TF, and MPs-TF were measured by enzyme-linked immunosorbent assay. We divided patients into 2 groups: thrombolysis group (n = 13) and nonthrombolysis group (n = 20). Furthermore, evaluation of the National Institutes of Health Stroke Scale and the Barthel Index was performed on the first day and the seventh day. RESULTS: Patients with ischemic stroke showed significantly lower plasma FVII, FVIIa-AT, and total TF levels than controls (median, 112.25% vs 132.05%, P = .004; 107.97 pmol/L vs 154.94 pmol/L, P < .001; 81.74 pg/mL vs 105.71 pg/mL, P < .001, respectively). In contrast, levels of plasma MPs-TF were significantly higher in patients with stroke compared to healthy controls (1.60 pg/mL vs 0.74 pg/mL, P < .001). Additionally, the thrombolysis group had lower FVII levels on the seventh day compared to the first day (median, 109.80% vs 115.74%, P = .04). CONCLUSION: Factor VII, FVIIa-AT, and total TF are decreased, while MPs-TF are elevated in patients with ischemic stroke. We observed a slight but significant effect of alteplase on FVII plasma levels.
[Mh] Termos MeSH primário: Antitrombina III/metabolismo
Fator VII/metabolismo
Acidente Vascular Cerebral/sangue
Terapia Trombolítica/métodos
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Feminino
Seres Humanos
Masculino
Meia-Idade
Projetos Piloto
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
9000-94-6 (Antithrombin III); 9001-25-6 (Factor VII)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:170522
[Lr] Data última revisão:
170522
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160214
[St] Status:MEDLINE
[do] DOI:10.1177/1076029616631424



página 1 de 397 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde